Up a level |
2022
Pensabene, A., van der Werf, P., Decarli, R., Banados, E., Meyer, R. A., Riechers, D., Venemans, B., Walter, F., Weiss, A., Brusa, M., Fan, X., Wang, F. and Yang, J. (2022). Unveiling the warm and dense ISM in z > 6 quasar host galaxies via water vapor emission. Astron. Astrophys., 667. LES ULIS CEDEX A: EDP SCIENCES S A. ISSN 1432-0746
2017
Corcoran, N. M., Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2017). Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain. Asia-Pac. J. Clin. Oncol., 13. S. 57 - 58. HOBOKEN: WILEY. ISSN 1743-7563
2016
Chowdhury, S., Shore, N., Saad, F., Higano, C. S., Fizazi, K., Iversen, P., Miller, K., Heidenreich, A., Ueda, T., Kim, C. S., Phung, D., Krivoshik, A., Wang, F., Wu, K. and Tombal, B. (2016). Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Ghatak, S., Niland, S., Schulz, J., Wang, F., Mauch, C., Krieg, T., Zigrino, P. and Eckes, B. (2016). Combined loss of integrins alpha 1 beta 1 and alpha 2 beta 1 results in reduced angiogenesis in mice. J. Invest. Dermatol., 136 (9). S. S255 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-1747
Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2016). Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Wang, F., Ghatak, S., Bruckner, P., Krieg, T. and Eckes, B. (2016). Characterization of mice devoid of integrins alpha 1 beta 1, alpha 2 beta 1 and alpha 11 beta 1. J. Invest. Dermatol., 136 (9). S. S182 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-1747